Isocitrate Dehydrogenase (IDH) inhibitors, 2018 - Competitive Landscape, Market and Pipeline Analysis - ResearchAndMarkets.com

DUBLIN--()--The "Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018 provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 8+ products along with 5+ companies involved. Agios Pharmaceuticals and Novartis are developing therapeutic drugs in the higher phase and Agios has been granted Orphan and Fast-track Designation both from the FDA.

Products covered by Phase:

  • Phase III, Phase II and Phase I
  • Pre-clinical and Discovery

Overview of pipeline development activities for Isocitrate Dehydrogenase IDH inhibitors

  • Pipeline analysis of 8+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
  • Therapeutic segmentation of products for Isocitrate Dehydrogenase (IDH) inhibitors.
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism of action.

Scope:

  • The report provides competitive pipeline landscape of Isocitrate Dehydrogenase (IDH) inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Isocitrate Dehydrogenase (IDH) inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Isocitrate Dehydrogenase (IDH) inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Isocitrate Dehydrogenase (IDH) inhibitors and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Companies Featured

  • Celgene Corporation
  • Agios Pharmaceuticals
  • Novartis
  • Bayer
  • Daiichi Sankyo Company
  • Agios Pharmaceuticals
  • GlaxoSmithKline
  • Evotec

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/m3clpb/isocitrate?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Enzymes

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Enzymes